EU Pharmacovigilance Fees Could Cripple Drug Firms, Says Pharma Industry
This article was originally published in The Pink Sheet Daily
Executive Summary
Fees set to be introduced to cover the cost of the European Medicines Agency’s part in improving drug safety could impose a huge burden on the EU pharmaceutical industry and lead to the closure of smaller firms, the industry says.